Blood Screening Market Size

ID: MRFR/MED/5434-HCR

85 Pages

Rahul Gotadki

September 2025

Blood Screening Market Research Report By Technology (Nucleic Acid Amplification Test, Enzyme-Linked Immunosorbent Assay, Next-Generation Sequencing), Product and Services (Reagents, Instruments) and End User (Hospitals and Clinics) - Forecast till 2032

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Blood Screening Size

Blood Screening Market Growth Projections and Opportunities

Various determinants shape the dynamics of the blood screening market. One major driver is the current increase in infectious diseases and chronic illnesses globally. Technological advancements also have a significant impact on the blood screening market. Relentless improvements in diagnostic tools and techniques refine the accuracy as well as effectiveness of blood screening tests. Such innovations have revolutionized blood screening, which enables precise detection of infections and genetic disorders, for instance, nucleic acid testing, polymerase chain reaction (PCR), and next-generation sequencing, among others. These technological improvements improve diagnostic capabilities while expanding the range of detectable conditions, thus contributing to market growth. Moreover, government initiatives and regulations also play a significant role in shaping this industry. The authorities' strict laws, coupled with mandated programs concerning health, contribute towards standardizing blood screening practices. They ensure that transfusions of blood, organs, or any other forms involve only appropriate usage of blood products. Also, public awareness campaigns leading to increased emphasis on preventive screenings and regular health checkups by members of society are helping boost the Blood Screening Market globally. However, economic factors also influence how people get to access these services as well as their affordability within some environments; availability, depending on the healthcare infrastructure available, may be costly, for example. Developed economies with mature healthcare systems often see higher adoption rates for advanced forms of technology in blood screening than developing countries do. Lastly, partnership strategies combined with mergers within the healthcare industry also determine how fast players gain or lose control over markets.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

The Global Blood Screening Market is projected to grow from 3.4 USD Billion in 2024 to 7.49 USD Billion by 2035.

Key Market Trends & Highlights

Blood Screening Key Trends and Highlights

The market is expected to experience a compound annual growth rate (CAGR) of 7.45 percent from 2025 to 2035.
By 2035, the market valuation is anticipated to reach 7.49 USD Billion, indicating robust growth potential.
In 2024, the market is valued at 3.4 USD Billion, reflecting a strong foundation for future expansion.
Growing adoption of advanced screening technologies due to increasing awareness of bloodborne diseases is a major market driver.

Blood Screening Market

CAGR

7.45%

Market Size & Forecast

2024 Market Size	3.4 (USD Billion)
2035 Market Size	7.49 (USD Billion)
CAGR (2025-2035)	7.45%
Largest Regional Market Share in 2024	latin_america)

Major Players

BioMerieux, Siemens Healthineers, Thermo Fisher Scientific Inc, Roche Diagnostics, Becton, Dickinson, and Company

Market Trends

Emergence of automated molecular platforms for blood screening to propel market growth

Automated molecular platforms for blood screening are becoming a popular strategy among leading market players, fueling market growth. Blood screening tests aim to ensure the security of donated blood units and to find any signs of transmissible transfusion infections (TTIs) in the blood. The transition from manual to automated screening platforms has been critical in identifying contagious transfusion infections (TTIs) in blood samples. In the transfusion screening process, growing automation is anticipated to reduce human error. These screening tests generally impact most medical decisions in blood banks and hospitals.

For instance, F. Hoffmann-La Roche Ltd. confirmed the CE-IVD launch of "cobas" in December 2019, which is intended to be utilized for blood donation screening and locates the Zika virus in human plasma. As a result, the adoption of these automated molecular platforms in blood donation facilities has increased due to the introduction of these platforms by key players. This will drive the growth of the blood screening market CAGR over the forecasted period.

Other key factors boosting the development of the Blood Screening Market revenue include increasing blood donations and blood donors, raising awareness of the safety of donated blood, growing the prevalence of infectious diseases, and various government initiatives. The number of blood donations worldwide in 2022 is estimated to be around 118.5 million. Additionally, the WHO suggests that blood donations be screened for illnesses before use, including hepatitis B, syphilis, and other sexually transmitted diseases (STDs).

The ongoing advancements in blood screening technologies, coupled with increasing regulatory emphasis on safety and quality, appear to be driving a transformative shift in the global landscape of blood diagnostics.

U.S. Food and Drug Administration (FDA)

Blood Screening Market Market Drivers

Rising Prevalence of Bloodborne Diseases

The increasing incidence of bloodborne diseases such as HIV, Hepatitis B, and Hepatitis C is a primary driver for the Global Blood Screening Market Industry. As awareness regarding these diseases grows, the demand for effective screening methods intensifies. For instance, the World Health Organization reports that millions are affected globally, necessitating robust screening protocols. This heightened focus on disease prevention is projected to contribute significantly to the market's growth, with the industry expected to reach 3.4 USD Billion in 2024 and potentially 7.49 USD Billion by 2035, reflecting a compound annual growth rate of 7.45% from 2025 to 2035.

Market Segment Insights

Blood Screening Technology Insights

Based on materials, the Blood Screening Market segmentation includes nucleic acid amplification tests, enzyme-linked immunosorbent assay, and next-generation sequencing. The nucleic acid amplification tests segment held the majority share in 2022, contributing to around ~45-47% of the Blood Screening Market revenue. The advanced benefits of nucleic acid amplification test technology, such as high specificity and sensitivity for early detection, account for most of the share. The test detects nucleic acid sooner than other screening methods, narrowing the window period for HBV, HCV, and HIV infections.

In addition, its largest share is also influenced by the technology's widespread use in hospitals, clinical labs, and blood banks. Moreover, the widespread adoption of this technology in developing and emerging markets creates new avenues for the segment's expansion.

Figure 1: Global Blood Screening Market, by Technology, 2022 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

Blood Screening Product & Services Insights

Applications have bifurcated the Blood Screening Market data into reagents and instruments. The reagents segment dominated the market in 2022 and is anticipated to be the faster-growing segment in the forecast period 2024-2032. Reagents, a recurring expense, are widely used in immunoassays and molecular tests. Factors such as increased blood donations and transfusion-related screenings, as well as the increasing prevalence of infectious diseases, are driving the growth of this segment. Additionally, the COVID-19 outbreak has increased serological testing, which has helped grow this market segment.

These kits have uses in clinical chemistry, polymerase chain reaction (PCR), diabetes, in vitro and molecular diagnostics, test strips, and the detection of illicit drugs. Reagents and kits are also used privately or at the Point of Care (POC) for DNA lineage analysis, glucose strips, and at-home pregnancy tests.

Blood Screening End User Insights

Based on End Users, the global Blood Screening Market segmentation has been divided into hospitals, clinics, and others. Hospitals held the most prominent segment share in 2022 due to the increasing frequency of blood transfusion procedures in these settings. Many hospitals worldwide use patient blood management programs to help with transfusion, and screening practices, primarily to improve patient outcomes, cut costs and conserve blood units. Moreover, growing collaborations between blood centers and hospitals fuel the adoption of blood screening tests in these settings, driving the blood screening market growth throughout the forecast period.

In December 2022, PredOmix introduced a novel blood test called OncoVeryx-F, which has a unique capability to accurately detect early-stage malignancies in women with a remarkable accuracy rate of 98%. Utilizing cutting-edge metabolomics technology in conjunction with artificial intelligence (AI), this novel advancement will facilitate the detection of early-stage malignancies through screening processes. The screening method, specifically tailored for the female population, effectively and precisely detects cancer at an early stage, prior to the initiation of tumor formation. The patented technology known as OncoVeryx-F integrates metabolomics and artificial intelligence methodologies for the purpose of early cancer detection.

July 2023: Quest Diagnostics has recently introduced the inaugural direct-to-consumer blood test designed to identify atypical levels of beta amyloid, a crucial protein associated with Alzheimer's disease that may manifest years prior to the onset of dementia symptoms. The news is a result of the recent regulatory clearance in the United States of Leqembi, a pharmaceutical product developed by Eisai in collaboration with Biogen. Leqembi is designed to eliminate amyloid from the brain and has demonstrated efficacy in slowing the progression of Alzheimer's disease in individuals in the early stages of the condition.

Get more detailed insights about Blood Screening Market Research Report - Forecast till 2032

Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Blood Screening market accounted for USD 1.14 billion in 2022 and is likely to exhibit a significant CAGR growth over the study period. The region's largest share is mainly attributed to rising blood transfusion-related screenings, increasing infectious disease prevalence, an aging population, the need for early disease detection and monitoring, rising healthcare expenditure, and the growing adoption of technologically advanced blood screening technologies.

This region's dominance is further attributed to increased blood donors, widespread implementation of blood screening procedures, and improved patient affordability.

Further, the major countries studied in the global market report are the U.S., Germany, Canada, France, the UK, Spain, Italy, Japan, India, Australia, China, South Korea, and Brazil.

Figure 3: BLOOD SCREENING MARKET SHARE BY REGION 2022 (%)

Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

The second-largest market share belongs to the European blood screening market, where respiratory illnesses and cancer are becoming more common. Rising government support and increased private-sector investment in the research and development of various blood screening tests are driving revenue growth in this region. For instance, F. Hoffmann-La Roche Ltd. introduced the Cobas Zika test for Cobas 6800/8800 Systems on December 16, 2019. The Cobas Zika test is designed to screen blood donations in Europe for Zika virus infection by finding RNA in human plasma samples.

In addition, the European Union has made blood screening for HCV, HBV, HIV, parvovirus-19, and other viruses mandatory. Further, the German blood screening market held the largest market share, and the UK blood screening market was the fastest-growing market in the European region.

The Asia-Pacific Blood Screening Market is projected to grow at the fastest CAGR from 2024 to 2032, owing to rising patient affordability and key industry players' increased focus on emerging markets. Japan, India, China, Singapore, and Australia contribute significantly to the market in the Asia Pacific region. Moreover, China’s blood screening market held the largest market share, and the Indian blood screening market was the fastest-growing market in the Asia-Pacific region.

India's blood screening market differs from other Asia Pacific nations like China and Japan as of laxer regulatory requirements and the importation of the necessary equipment and materials. Expanded investments by private and international entities, which may help offer practical tests at lower prices, are expected to lead to significant growth in the Indian blood screening industry. India's well-connected network of clinical laboratories and healthcare facilities is accelerating the adoption of blood screening methods.

Key Players and Competitive Insights

The competitive landscape is semi-consolidated, with several domestic and international blood screening industry players operating globally. Major market players are investing heavily in research and development to develop more innovative and advanced techniques that minimize turnaround time and improve the effectiveness and accuracy of crossmatch screening. Key players use various market development strategies, including investing in adapting cutting-edge techniques, launching new technologies, mergers & acquisitions, and regional expansion to capture the largest share of global revenue.

Blood screening industry competitors must provide cost-effective products and services to develop and sustain in an intensely challenging and rising global market environment. The blood screening market major players, such as BioMerieux, Siemens Healthineers, Thermo Fisher Scientific Inc, and others, are working to increase industry demand by investing in research and development activities to ensure constant innovation. The global blood screening industry has recently provided some of the most substantial advantages to reagents and instruments.

Roche Diagnostics (Switzerland) is a company that provides diagnostic system solutions for hospitals, clinics, laboratories, and doctors' offices. The company creates, manufactures, and supports in-vitro diagnostic and bioanalytical instruments and software systems. It also provides test systems, molecular diagnostic reagents, blood screening products, diagnostic analysis systems, and workflow solutions. Blood glucose meters and point-of-care testing equipment are among its primary offerings. The company offers services and products to commercial diagnostic laboratories, hospitals, researchers, healthcare professionals, and pharmacists. Roche Diagnostics (Switzerland) purchased TIB Molbiol Group (Germany) in September 2021.

This acquisition will broaden Roche's portfolio of molecular diagnostics solutions, including assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Also, Becton, Dickinson, and Company, or BD, is a multinational clinical technology company based in the United States that produces and distributes medical devices, indicator systems, and reagents. Additionally, in certain regions, BD offers consulting and analytics services. In March 2020, B.D. announced the launch of a singular blood screening test that can identify antibodies in blood to confirm current or previous COVID-19 exposure in less than 15 minutes.

Key Companies in the Blood Screening Market market include

Industry Developments

June 2021: Grail, an American pharmaceutical and biotechnology company, has announced the release of the Galleri blood screening test, an advanced multi-cancer screening diagnostic that can detect the presence of multiple cancers. This test will assist the company in screening approximately 50 million people after its launch to obtain full FDA approval by 2023.

May 2021: Tzar Labs, a molecular diagnostics company, and Epigeneres Biotechnology have announced the development of cancer tests for early detection. This test, which will be available by the end of 2023, will assist in determining the various stages of the disease. The company's accuracy rates for cancer screening tests are very high, and it has demonstrated results for all forms of cancer.

October 2020: Siemens Healthineers has announced the availability of its laboratory-based total immunoglobulin test1 for identifying SARS-CoV-2 IgM and IgG immunoglobulin in the blood throughout the world. The ability to identify patients who have an adaptive immune response is made possible by the complete antibody test.

Future Outlook

Blood Screening Market Future Outlook

The Global Blood Screening Market is projected to grow at a 7.45% CAGR from 2024 to 2035, driven by technological advancements, increasing disease prevalence, and rising awareness.

New opportunities lie in:

Developing point-of-care testing solutions to enhance accessibility and speed.
Investing in AI-driven data analytics for improved screening accuracy.
Expanding partnerships with healthcare providers to broaden market reach.

By 2035, the market is expected to exhibit robust growth, reflecting advancements and heightened demand.

Market Segmentation

Blood Screening End User Outlook

Hospitals
Clinics
Others

Blood Screening Regional Outlook

US
Canada
Germany
France
UK
Italy
Spain
Rest of Europe
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East
Africa
Latin America

Blood Screening Technology Outlook

Nucleic Acid Amplification Test
Enzyme-Linked Immunosorbent Assay
Next-Generation Sequencing

Blood Screening Product & Services Outlook

Reagents
Instrument

Report Scope

Report Attribute/Metric	Details
Market Size 2023	USD 2.70 billion
Market Size 2024	USD 3.40 billion
Market Size 2032	USD 5.60 billion
Compound Annual Growth Rate (CAGR)	10.20% (2024-2032)
Base Year	2023
Market Forecast Period	2024-2032
Historical Data	2019-2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Market Competitive Landscape, Revenue Forecast, Growth Factors, and Trends
Segments Covered	Technology, Product & Services, End User, and Region
Geographies Covered	Europe, Asia Pacific, North America, and the Rest of the World
Countries Covered	The U.S., Germany, Canada, the UK, France, Italy, Spain, Japan, India, Australia, China, South Korea, and Brazil
Key Companies Profiled	BioMerieux, Bio-Rad Laboratories Inc, Siemens Healthineers, Ortho Clinical Diagnostics Inc, and Thermo Fisher Scientific Inc
Key Market Opportunities	· Technology improvements in blood screening equipment · Increase in the number of point-of-care (POC) testing facilities
Key Market Dynamics	· Increasing prevalence of infectious and chronic diseases worldwide · Increased demands for CBC tests during the COVID-19 pandemic

Market Highlights

Author

Rahul Gotadki

Assistant Manager

She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Latest Comments

John Doe

[email protected]

This is a great article! Really helped me understand the topic better.

Posted on July 23, 2025, 10:15 AM

Jane Smith

[email protected]

Thanks for sharing this. I’ve bookmarked it for later reference.

Posted on July 22, 2025, 7:45 PM

View All

FAQs

How much is the blood screening market?

The Blood Screening Market size was valued at USD 2.70 Billion in 2023.

What is the growth rate of the blood screening market?

The global market is anticipated to grow at a CAGR of 10.20% over the projected period, 2024-2032.

Which region held the largest market revenue share in the blood screening market?

North America had the largest revenue share of the global market.

Who are the key players in the blood screening market?

The key players in the global market are BioMerieux, Bio-Rad Laboratories Inc, Siemens Healthineers, Ortho Clinical Diagnostics Inc, and Thermo Fisher Scientific Inc.

Which technology led the blood screening market?

The nucleic acid amplification test category dominated the market in 2023.

Which end-user had the largest market share in the blood screening market?

Hospitals had the most significant global market share.

'Table of Contents:
Chapter 1. Report
Prologue
Chapter 2. Market Introduction
1. Definition
Scope of the Study
1. Research
Objective
1. Assumptions
  1. Limitations
Chapter
Research Methodology
1. Introduction
2. Primary Research
Secondary Research
1. Market Size
Estimation
Chapter 4. Market Dynamics
Drivers
1. Restraints
Opportunities
1. Challenges
2. Macroeconomic Indicators
3. Technology
Trends & Assessment
Chapter 5. Market Factor Analysis
1. Porter’s Five Forces Analysis
Bargaining Power of Suppliers
1. Bargaining
Power of Buyers
1. Threat of New Entrants
  1. Threat of Substitutes
  2. Intensity of Rivalry
Value Chain Analysis
1. Investment Feasibility Analysis
2. Pricing Analysis
Chapter 6. Global
Blood Screening Market, by Technology
1. Introduction
2. Nucleic Acid Amplification Test (NAT)
  1. Transcription-Mediated
Amplification (TMA)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.2.2 Real-Time
Polymerase Chain Reaction (PCR)
Market Estimates & Forecast, by Region,
2030
Enzyme-Linked Immunosorbent Assay (ELISA)
1. ELISA Market, By Platform
Market Estimates &
Forecast, by Country, 2023-2030
1. ELISA Market, By Generation
Market
Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast,
by Country, 2023-2030
1. Rapid Tests
Market Estimates
& Forecast, by Region, 2023-2030
Market
Estimates & Forecast, by Country, 2023-2030
1. Next-Generation
Sequencing (NGS)
Market Estimates & Forecast, by Country, 2023-2030
1. Western Blotting
Market Estimates & Forecast, by
Region, 2023-2030
Market Estimates
& Forecast, by Country, 2023-2030
Chapter 7. Global Blood
Screening Market, by Product and Services
1. Introduction
2. Reagent and kits
  1. NAT Reagents &
Kits
1. ELISA Reagents & Kits
2. Enzymes and Polymerases
Market Estimates & Forecast, by Country, 2023-2030
Standards and Controls
Market Estimates & Forecast, by Country,
1. Probes and Primers
Forecast, by Region, 2023-2030
1. Buffers,
Nucleotides, and Solutions
1. Immunosorbents
2. Controls
Market Estimates & Forecast, by Country, 2023-2030
Instruments
1. Rental Purchase
by Region, 2023-2030
1. Outright Purchase
2. Software
and services
Chapter 8. Global
Blood Screening Market, By End User
1. Hospitals
Clinics
Market Estimates & Forecast,
1. Research Institutes and
Academic Center
1. Blood Banks
2. Others
Global Blood Screening Market, by Region
Introduction
1. Americas
  1. North
America
1. US
  1. Canada
  2. South America
2. Europe
Western Europe
1. Germany
France
1. Italy
  1. Spain
  2. Eastern Europe
2. Asia-Pacific
  1. Japan
  2. China
India
1. Australia
  1. South
Korea
1. Rest of Asia-Pacific
2. Middle
East & Africa
1. Middle East
Africa
Chapter 10. Company Landscape
1. Introduction
2. Market
Share Analysis
1. Key Development &
Strategies
Chapter 11. Company Profiles
1. Grifols
  1. Company
Overview
1. Product and Services Overview
  1. Financials Overview
Key Developments
1. SWOT Analysis
2. F. Hoffmann-La Roche
Company Overview
1. Product
and Services Overview
1. Financial
  1. Key Developments
  2. SWOT Analysis
Abbott Laboratories
1. Company Overview
  1. Product and Services Overview
  2. Financial Overview
  3. Key
Development
1. SWOT Analysis
2. Biomérieux
  1. Company
  2. Product and Services Overview
  3. Financial Overview
Key Development
1. SWOT Analysis
2. Bio-Rad Laboratories, Inc.
  2. Product
  3. Financial
  4. Key Developments
SWOT Analysis
Siemens Healthineers (A Subsidiary of Siemens AG)
1. 1. Product
  2. Financial
  3. Key Developments
Ortho Clinical Diagnostics, Inc.
1. Overview
  1. Product and Services Overview
  2. Financial Overview
  4. SWOT Analysis
2. Thermo Fisher Scientific, Inc.
Overview
1. Product and Services
  1. Financials
  2. Key Developments
SWOT Analysis
1. Beckman Coulter (A Subsidiary of
Danaher Corporation)
1. Overview
  1. Product and Services Overview
Financials
1. Key Developments
  1. SWOT Analysis
2. Becton, Dickinson
and Company
1. Overview
Product and Services Overview
1. 1. Key Developments
  2. SWOT Analysis
Chapter 12
MRFR Conclusion
1. Key Findings
  1. From CEO’s Viewpoint
  2. Unmet Needs of the Market
Key Companies to Watch
1. Predictions
for the Blood Screening Market Industry
Chapter 13. Appendix
LIST OF TABLES:
Table 1 Global Blood Screening
Market Synopsis, 2023-2030
Table 2 Global Blood
Screening Market Estimates and Forecast, 2023-2030 (USD Million)
Table 3
Global Blood Screening Market, by Region, 2023-2030 (USD Million)
Table 4 Global Blood Screening Market, by Technology,
2030 (USD Million)
Table 5 Global Blood Screening,
by Product and Services, 2023-2030 (USD Million)
Table 6
Global Blood Screening Market, by End User, 2023-2030 (USD Million)
Table 7
North America: Blood Screening Market, by Technology, 2023-2030
(USD Million)
Table 8 North America: Blood Screening, by Product and Services,
Table 9 North America: Blood Screening
Market, by End User, 2023-2030 (USD Million)
Table 10 US: Blood
Screening Market, by Technology, 2023-2030 (USD Million)
Table 11
US: Blood Screening Market, by Product and Services, 2023-2030 (USD Million)
Table 12 US: Blood Screening Market, by End User, 2023-2030 (USD
Million)
Table 13 Canada: Blood Screening Market, by Technology,
Table 14 Canada: Blood Screening Market,
Table 15 Canada:
Blood Screening Market, by End User, 2023-2030 (USD Million)
Table 16
South America: Blood Screening Market, by Technology, 2023-2030 (USD Million)
Table 17 South America: Blood Screening Market, by Product and Services,
Table 18 South America: Blood Screening
Table 19 Europe:
Blood Screening Market, by Technology, 2023-2030 (USD Million)
Table 20
Europe: Blood Screening Market, by Product and Services, 2023-2030 (USD Million)
Table 21 Europe: Blood Screening Market, by End User, 2023-2030
(USD Million)
Table 22 Western Europe: Blood Screening Market,
by Technology, 2023-2030 (USD Million)
Table 23 Western Europe:
Blood Screening Market, by Product and Services, 2023-2030 (USD Million)
Table
Western Europe: Blood Screening Market, by End User, 2023-2030(USD
Table 25 Eastern Europe: Blood Screening Market, by
Technology, 2023-2030 (USD Million)
Table 26 Eastern Europe:
Eastern Europe: Blood Screening Market, by End User, 2023-2030
Table 28 Asia-Pacific: Blood Screening Market,
Table 29 Asia-Pacific:
Asia-Pacific: Blood Screening Market, by End User, 2023-2030 (USD
Table 31 Middle East & Africa: Blood Screening by
Market, by Technology, 2023-2030 (USD Million)
Table 32 Middle
East & Africa: Blood Screening Market, by Product and Services, 2023-2030 (USD
Table 33 Middle East & Africa Blood Screening Market,
by End User, 2023-2030 (USD Million)
LIST OF FIGURES:
Figure 1
Research Process
Figure 2 Market Structure for Global
Blood Screening Market
Figure 3 Market Dynamics for Global
Blood Screening Market
Figure 4 Global Blood Screening
Market Share, by Technology, 2023
Figure 5 Global Blood Screening
Market Share, by Product and Services, 2023
Figure 6 Global
Blood Screening Market Share, by End User, 2023
Figure 7 Global
Blood Screening Market Share, by Region, 2023
Figure 8 North
America: Blood Screening Market Share, by Country, 2023
Figure 9
Europe: Blood Screening Market Share, by Country, 2023
Figure 10 Asia-Pacific:
Blood Screening Market Share, by Country, 2023
Figure 11 Middle
East & Africa: Blood Screening Market Share, by Country, 2023
Figure 12
Global Blood Screening Market: Company Share Analysis, 2023 (%)
Figure
13 Grifols: Key Financials
Figure 14 Grifols: Segmental
Revenue
Figure 15 Grifols: Geographical Revenue
Figure 16 F.
Hoffmann-La Roche: Key Financials
Figure 17 F. Hoffmann-La
Roche: Segmental Revenue
Figure 18 F. Hoffmann-La Roche: Geographical
Figure 19 Abbott Laboratories: Key Financials
20 Abbott Laboratories: Segmental Revenue
Figure 21 Abbott
Laboratories: Geographical Revenue
Figure 22 Biomérieux:
Key Financials
Figure 23 Biomérieux: Segmental Revenue
Figure 24 Biomérieux: Geographical Revenue
25 Bio-Rad Laboratories, Inc.: Key Financials
Figure 26 Bio-Rad
Laboratories, Inc.: Segmental Revenue
Figure 27 Bio-Rad Laboratories,
Inc.: Geographical Revenue
Figure 28 Siemens Healthineers
(A Subsidiary of Siemens AG): Key Financials
Figure 29 Siemens
Healthineers (A Subsidiary of Siemens AG): Segmental Revenue
Figure 30 Siemens
Healthineers (A Subsidiary of Siemens AG): Geographical Revenue
Figure 31 Ortho
Clinical Diagnostics, Inc.: Key Financials
Figure 32 Ortho
Clinical Diagnostics, Inc.: Segmental Revenue
Figure 33 Ortho
Clinical Diagnostics, Inc.: Geographical Revenue
Figure 34 Thermo
Fisher Scientific, Inc.: Key Financials
Figure 35 Thermo Fisher
Scientific, Inc.: Segmental Revenue
Figure 36 Thermo Fisher
Scientific, Inc.: Geographical Revenue
Figure 37 Beckman Coulter
(A Subsidiary of Danaher Corporation): Key Financials
Figure 38 Beckman
Coulter (A Subsidiary of Danaher Corporation): Segmental Revenue
Figure 39
Beckman Coulter (A Subsidiary of Danaher Corporation): Geographical Revenue
Figure 40 Becton, Dickinson and Company: Key Financials
41 Becton, Dickinson and Company: Segmental Revenue
42 Becton, Dickinson and Company: Geographical Revenue'

Blood Screening Market Segmentation

Blood Screening Technology Outlook (USD Billion, 2019-2030)

Nucleic Acid Amplification Test
Enzyme-Linked Immunosorbent Assay
Next-Generation Sequencing

Blood Screening End User Outlook (USD Billion, 2019-2030)

Hospitals
Clinics
Others

Blood Screening Product & Services Outlook (USD Billion, 2019-2030)

Reagents
Instrument

Blood Screening Regional Outlook (USD Billion, 2019-2030)

North America Outlook (USD Billion, 2019-2030)
- North America Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- North America Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- North America Blood Screening by Product & Services
  - Reagents
  - Instrument
- US Outlook (USD Billion, 2019-2030)
- US Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- US Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- US Blood Screening by Product & Services
  - Reagents
  - Instrument
- CANADA Outlook (USD Billion, 2019-2030)
- CANADA Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- CANADA Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- CANADA Blood Screening by Product & Services
  - Reagents
  - Instrument
Europe Outlook (USD Billion, 2019-2030)
- Europe Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Europe Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Europe Blood Screening by Product & Services
  - Reagents
  - Instrument
- Germany Outlook (USD Billion, 2019-2030)
- Germany Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Germany Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Germany Blood Screening by Product & Services
  - Reagents
  - Instrument
- France Outlook (USD Billion, 2019-2030)
- France Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- France Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- France Blood Screening by Product & Services
  - Reagents
  - Instrument
- UK Outlook (USD Billion, 2019-2030)
- UK Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- UK Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- UK Blood Screening by Product & Services
  - Reagents
  - Instrument
- ITALY Outlook (USD Billion, 2019-2030)
- ITALY Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- ITALY Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- ITALY Blood Screening by Product & Services
  - Reagents
  - Instrument
- SPAIN Outlook (USD Billion, 2019-2030)
- Spain Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Spain Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Spain Blood Screening by Product & Services
  - Reagents
  - Instrument
- Rest Of Europe Outlook (USD Billion, 2019-2030)
- Rest Of Europe Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- REST OF EUROPE Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- REST OF EUROPE Blood Screening by Product & Services
  - Reagents
  - Instrument
Asia-Pacific Outlook (USD Billion, 2019-2030)
- Asia-Pacific Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Asia-Pacific Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Asia-Pacific Blood Screening by Product & Services
  - Reagents
  - Instrument
- China Outlook (USD Billion, 2019-2030)
- China Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- China Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- China Blood Screening by Product & Services
  - Reagents
  - Instrument
- Japan Outlook (USD Billion, 2019-2030)
- Japan Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Japan Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Japan Blood Screening by Product & Services
  - Reagents
  - Instrument
- India Outlook (USD Billion, 2019-2030)
- India Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- India Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- India Blood Screening by Product & Services
  - Reagents
  - Instrument
- Australia Outlook (USD Billion, 2019-2030)
- Australia Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Australia Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Australia Blood Screening by Product & Services
  - Reagents
  - Instrument
- Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)
- Rest of Asia-Pacific Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Rest of Asia-Pacific Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Rest of Asia-Pacific Blood Screening by Product & Services
  - Reagents
  - Instrument
Rest of the World Outlook (USD Billion, 2019-2030)
- Rest of the World Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Rest of the World Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Rest of the World Blood Screening by Product & Services
  - Reagents
  - Instrument
- Middle East Outlook (USD Billion, 2019-2030)
- Middle East Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Middle East Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Middle East Blood Screening by Product & Services
  - Reagents
  - Instrument
- Africa Outlook (USD Billion, 2019-2030)
- Africa Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Africa Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Africa Blood Screening by Product & Services
  - Reagents
  - Instrument
- Latin America Outlook (USD Billion, 2019-2030)
- Latin America Blood Screening by Technology
  - Nucleic Acid Amplification Test
  - Enzyme-Linked Immunosorbent Assay
  - Next-Generation Sequencing
- Latin America Blood Screening by End User
  - Hospitals
  - Clinics
  - Others
- Latin America Blood Screening by Product & Services
  - Reagents
  - Instrument

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027